Consultative meeting Registrar of Medicines Pharmaceutical Industry Ms

  • Slides: 23
Download presentation
Consultative meeting Registrar of Medicines & Pharmaceutical Industry Ms Mandisa Hela Medicines Regulatory Affairs

Consultative meeting Registrar of Medicines & Pharmaceutical Industry Ms Mandisa Hela Medicines Regulatory Affairs Department of Health 4 September 2008

Overview l l l Pharmaceutical Industry: Compliance with c. GMP Available Assistance: dti Marketing

Overview l l l Pharmaceutical Industry: Compliance with c. GMP Available Assistance: dti Marketing Code of Medicines: Proposed EDMS Other

? Pharmaceutical Industry: Compliance with c. GMP

? Pharmaceutical Industry: Compliance with c. GMP

Act 101 of 1965 l Act 101 of 1965: Amendment 2003 – – l

Act 101 of 1965 l Act 101 of 1965: Amendment 2003 – – l Licensing of Manufacturers Licensing of Wholesalers Implementation: 2004 – MCC issue licences 2004

History of GMP upgrade l Identify need for GMP upgrade – – – l

History of GMP upgrade l Identify need for GMP upgrade – – – l Medicines Control Council (MCC) Industry: need for export Jointly: Industry and MRA /MCC to obtain PIC/S membership GMP Guideline update – – – Previous GMP Guideline: 1998 PIC/S GMP Guideline adopt and adapt Workshop with Industry PIC/S GMP Guideline [12 workshops] Jan 2004 -Jan 2005 Compare GMP Guide to PIC/S Guide Incorporated Industry comment into PIC/S Guideline

History of GMP upgrade l GMP Guideline…. cont – – – MCC published updated

History of GMP upgrade l GMP Guideline…. cont – – – MCC published updated GMP Guideline: Nov 2005 Agreed-to Timeline with Industry for implementation: 6 months Inspection commencement: June 2006

History of GMP upgrade…. cont Identified specific areas of non-compliances: l HVAC l Self-inspections

History of GMP upgrade…. cont Identified specific areas of non-compliances: l HVAC l Self-inspections & Contract audits l Validation – Conference re specific aspects of guideline: February 2006 – MCC open-door policy to advise

Current GMP status Type Total No. Compliant Under Review MNC 8 8 0 Generic

Current GMP status Type Total No. Compliant Under Review MNC 8 8 0 Generic 32 16 16 Closed 4 (Generic)

? Assistance: dti

? Assistance: dti

? Marketing Code of Medicines: Proposed

? Marketing Code of Medicines: Proposed

Marketing Code of Medicines l Medicines Act: Section 18 C Enforceable Code of Practice

Marketing Code of Medicines l Medicines Act: Section 18 C Enforceable Code of Practice for the Marketing of Medicines

Comment: Marketing Code of Medicines l Proposed Marketing Code excludes: – – l Veterinary

Comment: Marketing Code of Medicines l Proposed Marketing Code excludes: – – l Veterinary medicines Complementary medicines Reference to legislation – – Text general e. g. “Minimum requirements” Spirit of code seems to support any efficacy claim with substantiation / reference

Comment: Marketing Code of Medicines l Marketing wording: “Safe” / “Natural” – – –

Comment: Marketing Code of Medicines l Marketing wording: “Safe” / “Natural” – – – l Clinical trials – l MCC registers: safety, efficacy and quality Natural versus manipulation Natural does not translate to “Safe” Text confusing / registered medicines? Quotations – Text confusing / unregistered indications?

Conclusion: Marketing Code of Medicines l l l Thanks to Industry for the effort

Conclusion: Marketing Code of Medicines l l l Thanks to Industry for the effort Clarification on issues raised Communication with the MRA Draft Amendment Bill of Act 101 states there “shall” be an enforceable Code Details will be in Regulations and Guideline documents – Comments invited

? EDMS Workflow Specification and Software Configuration Project

? EDMS Workflow Specification and Software Configuration Project

MRA Network Topology Slide 16

MRA Network Topology Slide 16

It is expected that the EDMS Project will provide the following within the scope

It is expected that the EDMS Project will provide the following within the scope of the configuration contract : – Conformance to local regulatory requirements – Conform to international regulatory standards – Conform to Government IT standards – Ability to perform search and retrieval operations on the information stored in the system – Ability to perform workflow management in-house – Provide web-enabled centralised control – Provide necessary tools to perform publication of updated information on website – Provide ability to maintain security/control via digital signatures – Ability to deliver version and iteration control – Provide a clear archiving strategy Slide 17

Major Indicators • Local Industry acceptance will be key with particular attention: - security,

Major Indicators • Local Industry acceptance will be key with particular attention: - security, compatibility of IT systems • Electronic process will satisfy environmental & archiving concerns • Different Databases integration at MRA • Project Management and transparent timeline management • Knowledge Management (Management reporting, supervision and efficiency) • Format cross indexing (MBR 1 MRF 1 e. CTD) • Work in progress, workshops, seminars to follow with all stakeholders • Pilot planned: February 2009 Slide 18

? Schedules to Act 101

? Schedules to Act 101

Schedules to Act 101: 5 Sept 08 l Government Gazette – – Newly developed

Schedules to Act 101: 5 Sept 08 l Government Gazette – – Newly developed entities e. g. Human Papillomavirus vaccine (S 4) New designer drugs with abuse potential e. g. 1 -Benzylpiperazine (BZP) (S 7)

Schedules to Act 101: 5 Sept 08 l Rescheduling based on new information Clotrimazole

Schedules to Act 101: 5 Sept 08 l Rescheduling based on new information Clotrimazole (S 1), a. when intended for human vaginal use specifically for the treatment of recurrent vaginal candidiasis; (S 4) and b. when intended for application to the skin. (S 4)

Schedules to Act 101: 5 Sept 08 Improved descriptions e. g. Hyaluronic Acids (S

Schedules to Act 101: 5 Sept 08 Improved descriptions e. g. Hyaluronic Acids (S 0, S 1, S 2, S 4) – Hyaluronic acid and its salts (S 1), when contained in preparations containing 2, 5 percent or more intended for topical application to the skin, except preparations containing less than 0, 25 percent when intended for topical use in terms of the provisions of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act 54 of 1972). (S 0, S 2, S 4)

END Drive safely

END Drive safely